Personalis, Inc. announced an expansion and extension of its strategic collaboration with Tempus AI, Inc. through 2029. This updated agreement adds colorectal cancer (CRC) to the existing exclusive commercialization agreement for the NeXT Personal ultra-sensitive, tumor-informed minimal residual disease (MRD) test.
The collaboration now covers cancer recurrence detection in four major areas: breast, lung, and colorectal cancers, and solid tumor immunotherapy monitoring. The addition of CRC follows compelling interim analysis results from the VICTORI study, presented at the 2025 American Association for Cancer Research (AACR) Annual Meeting, which demonstrated strong performance of NeXT Personal for detecting early signs of residual or recurrent CRC.
Under the updated terms, Tempus will pay Personalis $10 million upfront, $15 million in 2026, and up to $100 million in milestones. This deepened collaboration aims to accelerate the adoption of NeXT Personal, equipping oncologists with a powerful new tool to detect cancer recurrence earlier and manage patients with a more personalized approach.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.